Zika virus: Recent advances towards the development of vaccines and therapeutics

Viruses

Volumn 9, Issue 6, 2017, Pages

  McArthur, Monica A ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Animal models; Congenital Zika syndrome; Immunology; Vaccines; Zika virus

Indexed keywords

DNA VACCINE; EPITOPE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; RNA VACCINE; SUBUNIT VACCINE; VIRUS RNA; ZIKA VIRUS VACCINE; ANTIVIRUS AGENT; VIRUS VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; CELLULAR IMMUNITY; CLINICAL FEATURE; CONGENITAL ZIKA SYNDROME; CROSS REACTION; CYTOKINE RELEASE; DIAGNOSTIC TEST; DISEASE MODEL; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; MENINGOENCEPHALITIS; MICROCEPHALY; MYELITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYLOGENY; PRIMATE MODEL; REVIEW; RODENT MODEL; VIRAL TROPISM; VIRUS ISOLATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; ZIKA FEVER; ZIKA VIRUS; ANIMAL; DRUG EFFECTS; FEMALE; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFANT; MEDICAL RESEARCH; MOUSE; PATHOGENICITY; PREGNANCY; PREGNANCY COMPLICATION; PUBLIC HEALTH; UTERUS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; MICE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PUBLIC HEALTH; UTERUS; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85020935794     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v9060143     Document Type: Review

References (134)

1. WHO Situation Report 10 March 2017. Available online: http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf?ua=1 (accessed on 2 April 2017).
2. WHO Situation Report 24 November 2016. Available online: http://www.who.int/emergencies/zika-virus/situation-report/24-november-2016/en/ (accessed on 27 December 2016).
3. WHO Zika Situation Report 5 February 2016. Available online: http://apps.who.int/iris/bitstream/10665/204348/1/zikasitrep_5Feb2016_eng.pdf?ua=1 (accessed on 7 April 2017).
4. Dick, G.W.; Kitchen, S.F.; Haddow, A.J. Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 1952, 46, 509–520.
5. Duffy, M.R.; Chen, T.H.; Hancock, W.T.; Powers, A.M.; Kool, J.L.; Lanciotti, R.S.; Pretrick, M.; Marfel, M.; Holzbauer, S.; Dubray, C., et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N. Engl. J. Med. 2009, 360, 2536–2543, doi:10.1056/NEJMoa0805715.
6. Kuno, G.; Chang, G.J. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. Arch. Virol. 2007, 152, 687–696, doi:10.1007/s00705-006-0903-z.
7. Sirohi, D.; Chen, Z.; Sun, L.; Klose, T.; Pierson, T.C.; Rossmann, M.G.; Kuhn, R.J. The 3.8 A resolution cryo- EM structure of Zika virus. Science 2016, 352, 467–470, doi:10.1126/science.aaf5316.
8. Lindenbach, B.D.; Rice, C.M. Molecular biology of flaviviruses. Adv. Virus Res. 2003, 59, 23–61.
9. Best, S.M. The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling. J. Virol. 2017, 91, doi:10.1128/JVI.01970-16.
10. Ramaiah, A.; Dai, L.; Contreras, D.; Sinha, S.; Sun, R.; Arumugaswami, V. Comparative analysis of protein evolution in the genome of pre-epidemic and epidemic Zika virus. Infect. Genet. Evol. 2017, 51, 74–85, doi:10.1016/j.meegid.2017.03.012.
11. Song, B.H; Yun, S.I.; Woolley, M.; Lee, Y.M. Zika virus: History, epidemiology, transmission, and clinical presentation. J. Neuroimmunol. 2017, doi:10.1016/j.jneuroim.2017.03.001.
12. Cao-Lormeau, V.M.; Blake, A.; Mons, S.; Lastere, S.; Roche, C.; Vanhomwegen, J.; Dub, T.; Baudouin, L.; Teissier, A.; Larre, P., et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet 2016, 387, 1531–1539, doi:10.1016/S0140-6736(16)00562-6.
13. Oehler, E.; Watrin, L.; Larre, P.; Leparc-Goffart, I.; Lastere, S.; Valour, F.; Baudouin, L.; Mallet, H.; Musso, D.; Ghawche, F. Zika virus infection complicated by Guillain-Barre syndrome—Case report, French Polynesia, December 2013. Euro Surveill. 2014, 19, 20720.
14. Zika Virus Cases in the US. Available online: https://www.cdc.gov/zika/geo/united-states.html (accessed on 7 April 2017).
15. Kindhauser, M.K.; Allen, T.; Frank, V.; Santhana, R.S.; Dye, C. Zika: The origin and spread of a mosquitoborne virus. Bull. World Health Organ. 2016, 94, 675–686, doi:10.2471/BLT.16.171082.
16. Sharma, A.; Lal, S.K. Zika Virus: Transmission, Detection, Control, and Prevention. Front. Microbiol. 2017, 8, 110, doi:10.3389/fmicb.2017.00110.
17. D’Ortenzio, E.; Matheron, S.; Yazdanpanah, Y.; de Lamballerie, X.; Hubert, B.; Piorkowski, G.; Maquart, M.; Descamps, D.; Damond, F.; Leparc-Goffart, I. Evidence of Sexual Transmission of Zika Virus. N. Engl. J. Med. 2016, 374, 2195–2198, doi:10.1056/NEJMc1604449.
18. Foy, B.D.; Kobylinski, K.C.; Chilson Foy, J.L.; Blitvich, B.J.; Travassos da Rosa, A.; Haddow, A.D.; Lanciotti, R.S.; Tesh, R.B. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 2011, 17, 880–882, doi:10.3201/eid1705.101939.
19. Frank, C.; Cadar, D.; Schlaphof, A.; Neddersen, N.; Gunther, S.; Schmidt-Chanasit, J.; Tappe, D. Sexual transmission of Zika virus in Germany, April 2016. Euro Surveill. 2016, 21, doi:10.2807/1560-7917.ES.2016.21.23.30252.
20. Freour, T.; Mirallie, S.; Hubert, B.; Splingart, C.; Barriere, P.; Maquart, M.; Leparc-Goffart, I. Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016. Euro Surveill. 2016, 21, doi:10.2807/1560-7917.ES.2016.21.23.30254.
21. Barouch, D.H.; Thomas, S.J.; Michael, N.L. Prospects for a Zika Virus Vaccine. Immunity 2017, 46, 176–182, doi:10.1016/j.immuni.2017.02.005.
22. Waggoner, J.J.; Gresh, L.; Vargas, M.J.; Ballesteros, G.; Tellez, Y.; Soda, K.J.; Sahoo, M.K.; Nunez, A.; Balmaseda, A.; Harris, E., et al. Viremia and Clinical Presentation in Nicaraguan Patients Infected With Zika Virus, Chikungunya Virus, and Dengue Virus. Clin. Infect. Dis. 2016, 63, 1584–1590, doi:10.1093/cid/ciw589.
23. Grossi-Soyster, E.N.; LaBeaud, A.D. Clinical aspects of Zika virus. Curr. Opin. Pediatr. 2016, doi:10.1097/MOP.0000000000000449.
24. Brasil, P.; Calvet, G.A.; Siqueira, A.M.; Wakimoto, M.; de Sequeira, P.C.; Nobre, A.; Quintana Mde, S.; Mendonca, M.C.; Lupi, O.; de Souza, R.V., et al. Zika Virus Outbreak in Rio de Janeiro, Brazil: Clinical Characterization, Epidemiological and Virological Aspects. PLoS Negl. Trop. Dis. 2016, 10, e0004636, doi:10.1371/journal.pntd.0004636.
25. Calvet, G.A.; Santos, F.B.; Sequeira, P.C. Zika virus infection: Epidemiology, clinical manifestations and diagnosis. Curr. Opin. Infect. Dis. 2016, 29, 459–466, doi:10.1097/QCO.0000000000000301.
26. Arzuza-Ortega, L.; Polo, A.; Perez-Tatis, G.; Lopez-Garcia, H.; Parra, E.; Pardo-Herrera, L.C.; Rico-Turca, A.M.; Villamil-Gomez, W.; Rodriguez-Morales, A.J. Fatal Sickle Cell Disease and Zika Virus Infection in Girl from Colombia. Emerg. Infect. Dis. 2016, 22, 925–927, doi:10.3201/eid2205.151934.
27. Azevedo, R.S.; Araujo, M.T.; Martins Filho, A.J.; Oliveira, C.S.; Nunes, B.T.; Cruz, A.C.; Nascimento, A.G.; Medeiros, R.C.; Caldas, C.A.; Araujo, F.C., et al. Zika virus epidemic in Brazil. I. Fatal disease in adults: Clinical and laboratorial aspects. J. Clin. Virol. 2016, 85, 56–64, doi:10.1016/j.jcv.2016.10.024.
28. Dirlikov, E.; Ryff, K.R.; Torres-Aponte, J.; Thomas, D.L.; Perez-Padilla, J.; Munoz-Jordan, J.; Caraballo, E.V.; Garcia, M.; Segarra, M.O.; Malave, G., et al. Update: Ongoing Zika Virus Transmission—Puerto Rico, 1 November 2015–14 April 2016. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 451–455, doi:10.15585/mmwr.mm6517e2.
29. Sarmiento-Ospina, A.; Vasquez-Serna, H.; Jimenez-Canizales, C.E.; Villamil-Gomez, W.E.; Rodriguez- Morales, A.J. Zika virus associated deaths in Colombia. Lancet Infect. Dis. 2016, 16, 523–524, doi:10.1016/S1473-3099(16)30006-8.
30. Soares, C.N.; Brasil, P.; Carrera, R.M.; Sequeira, P.; de Filippis, A.B.; Borges, V.A.; Theophilo, F.; Ellul, M.A.; Solomon, T. Fatal encephalitis associated with Zika virus infection in an adult. J. Clin. Virol. 2016, 83, 63–65, doi:10.1016/j.jcv.2016.08.297.
31. Swaminathan, S.; Schlaberg, R.; Lewis, J.; Hanson, K.E.; Couturier, M.R. Fatal Zika Virus Infection with Secondary Nonsexual Transmission. N. Engl. J. Med. 2016, 375, 1907–1909, doi:10.1056/NEJMc1610613.
32. Brasil, P.; Sequeira, P.C.; Freitas, A.D.; Zogbi, H.E.; Calvet, G.A.; de Souza, R.V.; Siqueira, A.M.; de Mendonca, M.C.; Nogueira, R.M.; de Filippis, A.M., et al. Guillain-Barre syndrome associated with Zika virus infection. Lancet 2016, 387, 1482, doi:10.1016/S0140-6736(16)30058-7.
33. Yuki, N.; Hartung, H.P. Guillain-Barre syndrome. N. Engl. J. Med. 2012, 366, 2294–2304, doi:10.1056/NEJMra1114525.
34. Sandhu, S.K.; Hua, W.; MaCurdy, T.E.; Franks, R.L.; Avagyan, A.; Kelman, J.; Worrall, C.M.; Ball, R.; Nguyen, M. Near real-time surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2010/11 to 2013/14. Vaccine 2017, 35, 2986–2992, doi:10.1016/j.vaccine.2017.03.087.
35. Carteaux, G.; Maquart, M.; Bedet, A.; Contou, D.; Brugieres, P.; Fourati, S.; Cleret de Langavant, L.; de Broucker, T.; Brun-Buisson, C.; Leparc-Goffart, I., et al. Zika Virus Associated with Meningoencephalitis. N. Engl. J. Med. 2016, 374, 1595–1596, doi:10.1056/NEJMc1602964.
36. Mecharles, S.; Herrmann, C.; Poullain, P.; Tran, T.H.; Deschamps, N.; Mathon, G.; Landais, A.; Breurec, S.; Lannuzel, A. Acute myelitis due to Zika virus infection. Lancet 2016, 387, 1481, doi:10.1016/S0140-6736(16)00644-9.
37. Epidemiological Alert Increase of Microcephaly in the Northeast of Brazil. Available online: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=32285&lang=en (accessed on 7 April 2017).
38. Boeuf, P.; Drummer, H.E.; Richards, J.S.; Scoullar, M.J.; Beeson, J.G. The global threat of Zika virus to pregnancy: Epidemiology, clinical perspectives, mechanisms, and impact. BMC Med. 2016, 14, 112, doi:10.1186/s12916-016-0660-0.
39. Carvalho, M.D.; Miranda-Filho, D.B.; van der Linden, V.; Sobral, P.F.; Ramos, R.C.; Rocha, M.A.; Cordeiro, M.T.; de Alencar, S.P.; Nunes, M.L. Sleep EEG patterns in infants with congenital Zika virus syndrome. Clin. Neurophysiol. 2016, 128, 204–214, doi:10.1016/j.clinph.2016.11.004.
40. Cauchemez, S.; Besnard, M.; Bompard, P.; Dub, T.; Guillemette-Artur, P.; Eyrolle-Guignot, D.; Salje, H.; van Kerkhove, M.D.; Abadie, V.; Garel, C., et al. Association between Zika virus and microcephaly in French Polynesia, 2013–2015: A retrospective study. Lancet 2016, 387, 2125–2132, doi:10.1016/S0140-6736(16)00651-6.
41. Costello, A.; Dua, T.; Duran, P.; Gulmezoglu, M.; Oladapo, O.T.; Perea, W.; Pires, J.; Ramon-Pardo, P.; Rollins, N.; Saxena, S. Defining the syndrome associated with congenital Zika virus infection. Bull. World Health Organ. 2016, 94, 406A, doi:10.2471/BLT.16.176990.
42. De Paula Freitas, B.; de Oliveira Dias, J.R.; Prazeres, J.; Sacramento, G.A.; Ko, A.I.; Maia, M.; Belfort, R. Ocular Findings in Infants With Microcephaly Associated With Presumed Zika Virus Congenital Infection in Salvador, Brazil. JAMA Ophthalmol. 2016, doi:10.1001/jamaophthalmol.2016.0267.
43. de Paula Freitas, B.; Ko, A.I.; Khouri, R.; Mayoral, M.; Henriques, D.F.; Maia, M.; Belfort, R. Glaucoma and Congenital Zika Syndrome. Ophthalmology 2016, doi:10.1016/j.ophtha.2016.10.004.
44. Kleber de Oliveira, W.; Cortez-Escalante, J.; de Oliveira, W.T.; do Carmo, G.M.; Henriques, C.M.; Coelho, G.E.; Araujo de Franca, G.V. Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy—Brazil, 2015. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 242–247, doi:10.15585/mmwr.mm6509e2.
45. Frank, C.; Faber, M.; Stark, K. Causal or not: Applying the Bradford Hill aspects of evidence to the association between Zika virus and microcephaly. EMBO Mol. Med. 2016, 8, 305–307, doi:10.15252/emmm.201506058.
46. Rasmussen, S.A.; Jamieson, D.J.; Honein, M.A.; Petersen, L.R. Zika Virus and Birth Defects—Reviewing the Evidence for Causality. N. Engl. J. Med. 2016, doi:10.1056/NEJMsr1604338.
47. Martines, R.B.; Bhatnagar, J.; de Oliveira Ramos, A.M.; Davi, H.P.; Iglezias, S.D.; Kanamura, C.T.; Keating, M.K.; Hale, G.; Silva-Flannery, L.; Muehlenbachs, A., et al. Pathology of congenital Zika syndrome in Brazil: A case series. Lancet 2016, 388, 898–904, doi:10.1016/S0140-6736(16)30883-2.
48. Mlakar, J.; Korva, M.; Tul, N.; Popovic, M.; Poljsak-Prijatelj, M.; Mraz, J.; Kolenc, M.; Resman Rus, K.; Vesnaver Vipotnik, T.; Fabjan Vodusek, V., et al. Zika Virus Associated with Microcephaly. N. Engl. J. Med. 2016, 374, 951–958, doi:10.1056/NEJMoa1600651.
49. Tang, H.; Hammack, C.; Ogden, S.C.; Wen, Z.; Qian, X.; Li, Y.; Yao, B.; Shin, J.; Zhang, F.; Lee, E.M., et al. Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell 2016, 18, 587–590, doi:10.1016/j.stem.2016.02.016.
50. Quicke, K.M.; Bowen, J.R.; Johnson, E.L.; McDonald, C.E.; Ma, H.; O’Neal, J.T.; Rajakumar, A.; Wrammert, J.; Rimawi, B.H.; Pulendran, B., et al. Zika Virus Infects Human Placental Macrophages. Cell Host Microbe 2016, 20, 83–90, doi:10.1016/j.chom.2016.05.015.
51. Adams Waldorf, K.M.; Stencel-Baerenwald, J.E.; Kapur, R.P.; Studholme, C.; Boldenow, E.; Vornhagen, J.; Baldessari, A.; Dighe, M.K.; Thiel, J.; Merillat, S., et al. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat. Med. 2016, 22, 1256–1259, doi:10.1038/nm.4193.
52. Cugola, F.R.; Fernandes, I.R.; Russo, F.B.; Freitas, B.C.; Dias, J.L.; Guimaraes, K.P.; Benazzato, C.; Almeida, N.; Pignatari, G.C.; Romero, S., et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 2016, 534, 267–271, doi:10.1038/nature18296.
53. Li, C.; Xu, D.; Ye, Q.; Hong, S.; Jiang, Y.; Liu, X.; Zhang, N.; Shi, L.; Qin, C.F.; Xu, Z. Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice. Cell Stem Cell 2016, 19, 120–126, doi:10.1016/j.stem.2016.04.017.
54. Miner, J.J.; Cao, B.; Govero, J.; Smith, A.M.; Fernandez, E.; Cabrera, O.H.; Garber, C.; Noll, M.; Klein, R.S.; Noguchi, K.K., et al. Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise. Cell 2016, 165, 1081–1091, doi:10.1016/j.cell.2016.05.008.
55. Morrison, T.E. Diamond, M.S. Animal Models of Zika Virus Infection, Pathogenesis, and Immunity. J. Virol. 2017, 91, doi:10.1128/JVI.00009-17.
56. Dick, G.W. Zika virus. II. Pathogenicity and physical properties. Trans. R. Soc. Trop. Med. Hyg. 1952, 46, 521–534.
57. Wu, K.Y.; Zuo, G.L.; Li, X.F.; Ye, Q.; Deng, Y.Q.; Huang, X.Y.; Cao, W.C.; Qin, C.F.; Luo, Z.G. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res. 2016, 26, 645–654, doi:10.1038/cr.2016.58.
58. Elong Ngono, A.; Vizcarra, E.A.; Tang, W.W.; Sheets, N.; Joo, Y.; Kim, K.; Gorman, M.J.; Diamond, M.S.; Shresta, S. Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice. Cell Host Microbe 2017, 21, 35–46, doi:10.1016/j.chom.2016.12.010.
59. Lazear, H.M.; Govero, J.; Smith, A.M.; Platt, D.J.; Fernandez, E.; Miner, J.J.; Diamond, M.S. A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 2016, 19, 720–730, doi:10.1016/j.chom.2016.03.010.
60. Aliota, M.T.; Caine, E.A.; Walker, E.C.; Larkin, K.E.; Camacho, E.; Osorio, J.E. Characterization of Lethal Zika Virus Infection in AG129 Mice. PLoS Negl. Trop. Dis. 2016, 10, e0004682, doi:10.1371/journal.pntd.0004682.
61. Dowall, S.D.; Graham, V.A.; Rayner, E.; Atkinson, B.; Hall, G.; Watson, R.J.; Bosworth, A.; Bonney, L.C.; Kitchen, S.; Hewson, R. A Susceptible Mouse Model for Zika Virus Infection. PLoS Negl. Trop. Dis. 2016, 10, e0004658, doi:10.1371/journal.pntd.0004658.
62. Rossi, S.L.; Tesh, R.B.; Azar, S.R.; Muruato, A.E.; Hanley, K.A.; Auguste, A.J.; Langsjoen, R.M.; Paessler, S.; Vasilakis, N.; Weaver, S.C. Characterization of a Novel Murine Model to Study Zika Virus. Am. J. Trop. Med. Hyg. 2016, 94, 1362–1369, doi:10.4269/ajtmh.16-0111.
63. Chan, J.F.; Zhang, A.J.; Chan, C.C.; Yip, C.C.; Mak, W.W.; Zhu, H.; Poon, V.K.; Tee, K.M.; Zhu, Z.; Cai, J.P., et al. Zika Virus Infection in Dexamethasone-immunosuppressed Mice Demonstrating Disseminated Infection with Multi-organ Involvement Including Orchitis Effectively Treated by Recombinant Type I Interferons. EBioMedicine 2016, 14, 112–122, doi:10.1016/j.ebiom.2016.11.017.
64. Yockey, L.J.; Varela, L.; Rakib, T.; Khoury-Hanold, W.; Fink, S.L.; Stutz, B.; Szigeti-Buck, K.; Van den Pol, A.; Lindenbach, B.D.; Horvath, T.L., et al. Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain Infection. Cell 2016, 166, 1247–1256, doi:10.1016/j.cell.2016.08.004.
65. Arck, P.C.; Hecher, K. Fetomaternal immune cross-talk and its consequences for maternal and offspring’s health. Nat. Med. 2013, 19, 548–556, doi:10.1038/nm.3160.
66. Mysorekar, I.U.; Diamond, M.S. Modeling Zika Virus Infection in Pregnancy. N. Engl. J. Med. 2016, 375, 481–484, doi:10.1056/NEJMcibr1605445.
67. Dudley, D.M.; Aliota, M.T.; Mohr, E.L.; Weiler, A.M.; Lehrer-Brey, G.; Weisgrau, K.L.; Mohns, M.S.; Breitbach, M.E.; Rasheed, M.N.; Newman, C.M., et al. A Rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 2016, 7, 12204, doi:10.1038/ncomms12204.
68. Osuna, C.E.; Lim, S.Y.; Deleage, C.; Griffin, B.D.; Stein, D.; Schroeder, L.T.; Omange, R.; Best, K.; Luo, M.; Hraber, P.T., et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 2016, 22, 1448–1455, doi:10.1038/nm.4206.
69. Coffey, L.L.; Pesavento, P.A.; Keesler, R.I.; Singapuri, A.; Watanabe, J.; Watanabe, R.; Yee, J.; Bliss-Moreau, E.; Cruzen, C.; Christe, K.L., et al. Zika Virus Tissue and Blood Compartmentalization in Acute Infection of Rhesus macaques. PLoS ONE 2017, 12, e0171148, doi:10.1371/journal.pone.0171148.
70. Schneider, W.M.; Chevillotte, M.D.; Rice, C.M. Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 2014, 32, 513–545, doi:10.1146/annurev-immunol-032713-120231.
71. Bayer, A.; Lennemann, N.J.; Ouyang, Y.; Bramley, J.C.; Morosky, S.; Marques, E.T., Jr.; Cherry, S.; Sadovsky, Y.; Coyne, C.B. Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection. Cell Host Microbe 2016, 19, 705–712, doi:10.1016/j.chom.2016.03.008.
72. Versteeg, G.A.; Garcia-Sastre, A. Viral tricks to grid-lock the type I interferon system. Curr. Opin. Microbiol. 2010, 13, 508–516, doi:10.1016/j.mib.2010.05.009.
73. Grant, A.; Ponia, S.S.; Tripathi, S.; Balasubramaniam, V.; Miorin, L.; Sourisseau, M.; Schwarz, M.C.; Sanchez-Seco, M.P.; Evans, M.J.; Best, S.M., et al. Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling. Cell Host Microbe 2016, 19, 882–890, doi:10.1016/j.chom.2016.05.009.
74. Kotenko, S.V.; Gallagher, G.; Baurin, V.V.; Lewis-Antes, A.; Shen, M.; Shah, N.K.; Langer, J.A.; Sheikh, F.; Dickensheets, H.; Donnelly, R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4, 69–77, doi:10.1038/ni875.
75. Khan, S.; Woodruff, E.M.; Trapecar, M.; Fontaine, K.A.; Ezaki, A.; Borbet, T.C.; Ott, M.; Sanjabi, S. Dampened antiviral immunity to intravaginal exposure to RNA viral pathogens allows enhanced viral replication. J. Exp. Med. 2016, 213, 2913–2929, doi:10.1084/jem.20161289.
76. Sapparapu, G.; Fernandez, E.; Kose, N.; Bin, C.; Fox, J.M.; Bombardi, R.G.; Zhao, H.; Nelson, C.A.; Bryan, A.L.; Barnes, T., et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 2016, 540, 443–447, doi:10.1038/nature20564.
77. Stettler, K.; Beltramello, M.; Espinosa, D.A.; Graham, V.; Cassotta, A.; Bianchi, S.; Vanzetta, F.; Minola, A.; Jaconi, S.; Mele, F., et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 2016, 353, 823–826, doi:10.1126/science.aaf8505.
78. Swanstrom, J.A.; Plante, J.A.; Plante, K.S.; Young, E.F.; McGowan, E.; Gallichotte, E.N.; Widman, D.G.; Heise, M.T.; de Silva, A.M.; Baric, R.S. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. MBio 2016, 7, doi:10.1128/mBio.01123-16.
79. Abbink, P.; Larocca, R.A.; De La Barrera, R.A.; Bricault, C.A.; Moseley, E.T.; Boyd, M.; Kirilova, M.; Li, Z.; Ng’ang’a, D.; Nanayakkara, O., et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 2016, 353, 1129–1132, doi:10.1126/science.aah6157.
80. Muthumani, K.; Griffin, B.D.; Agarwal, S.; Kudchodkar, S.B.; Reuschel, E.L.; Choi, H.; Kraynyak, K.A.; Duperret, E.K.; Keaton, A.A.; Chung, C., et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines 2016, 1, doi:10.1038/npjvaccines.2016.21.
81. De Madrid, A.T.; Porterfield, J.S. The flaviviruses (group B arboviruses): A cross-neutralization study. J. Gen. Virol. 1974, 23, 91–96, doi:10.1099/0022-1317-23-1-91.
82. Fauci, A.S.; Morens, D.M. Zika Virus in the Americas—Yet Another Arbovirus Threat. N. Engl. J. Med. 2016, 374, 601–604, doi:10.1056/NEJMp1600297.
83. Barba-Spaeth, G.; Dejnirattisai, W.; Rouvinski, A.; Vaney, M.C.; Medits, I.; Sharma, A.; Simon-Loriere, E.; Sakuntabhai, A.; Cao-Lormeau, V.M.; Haouz, A., et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 2016, 536, 48–53, doi:10.1038/nature18938.
84. Dejnirattisai, W.; Supasa, P.; Wongwiwat, W.; Rouvinski, A.; Barba-Spaeth, G.; Duangchinda, T.; Sakuntabhai, A.; Cao-Lormeau, V.M.; Malasit, P.; Rey, F.A., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 2016, 17, 1102–1108, doi:10.1038/ni.3515.
85. Harrison, S.C. Immunogenic cross-talk between dengue and Zika viruses. Nat. Immunol. 2016, 17, 1010–1012, doi:10.1038/ni.3539.
86. Priyamvada, L.; Quicke, K.M.; Hudson, W.H.; Onlamoon, N.; Sewatanon, J.; Edupuganti, S.; Pattanapanyasat, K.; Chokephaibulkit, K.; Mulligan, M.J.; Wilson, P.C., et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl. Acad. Sci. USA 2016, 113, 7852–7857, doi:10.1073/pnas.1607931113.
87. Halstead, S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 2003, 60, 421–467.
88. Halstead, S.B. Antibodies determine virulence in dengue. Ann. N. Y. Acad. Sci. 2009, 1171, E48–E56, doi:10.1111/j.1749-6632.2009.05052.x.
89. Kliks, S.C.; Nisalak, A.; Brandt, W.E.; Wahl, L.; Burke, D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 1989, 40, 444–451.
90. Wahala, W.M.; Silva, A.M. The human antibody response to dengue virus infection. Viruses 2011, 3, 2374–2395, doi:10.3390/v3122374.
91. Duangchinda, T.; Dejnirattisai, W.; Vasanawathana, S.; Limpitikul, W.; Tangthawornchaikul, N.; Malasit, P.; Mongkolsapaya, J.; Screaton, G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. USA 2010, 107, 16922–16927, doi:10.1073/pnas.1010867107.
92. Rivino, L.; Lim, M.Q. CD4+ and CD8+ T-cell immunity to Dengue—Lessons for the study of Zika virus. Immunology 2016, doi:10.1111/imm.12681.
93. Simmons, C.P.; Dong, T.; Chau, N.V.; Dung, N.T.; Chau, T.N.; Thao le, T.T.; Dung, N.T.; Hien, T.T.; Rowland-Jones, S.; Farrar, J. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J. Virol. 2005, 79, 5665–5675, doi:10.1128/JVI.79.9.5665-5675.2005.
94. Weiskopf, D.; Angelo, M.A.; Sidney, J.; Peters, B.; Shresta, S.; Sette, A. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J. Virol. 2014, 88, 11383–11394, doi:10.1128/JVI.01108-14.
95. Weiskopf, D.; Sette, A. T-cell immunity to infection with dengue virus in humans. Front. Immunol. 2014, 5, 93, doi:10.3389/fimmu.2014.00093.
96. Akondy, R.S.; Monson, N.D.; Miller, J.D.; Edupuganti, S.; Teuwen, D.; Wu, H.; Quyyumi, F.; Garg, S.; Altman, J.D.; Del Rio, C., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 2009, 183, 7919–7930, doi:10.4049/jimmunol.0803903.
97. Cong, Y.; McArthur, M.A.; Cohen, M.; Jahrling, P.B.; Janosko, K.B.; Josleyn, N.; Kang, K.; Zhang, T.; Holbrook, M.R. Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells. PLoS Negl. Trop. Dis. 2016, 10, e0004709, doi:10.1371/journal.pntd.0004709.
98. Miller, J.D.; van der Most, R.G.; Akondy, R.S.; Glidewell, J.T.; Albott, S.; Masopust, D.; Murali-Krishna, K.; Mahar, P.L.; Edupuganti, S.; Lalor, S., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28, 710–722, doi:10.1016/j.immuni.2008.02.020.
99. Kim, J.H.; Patil, A.M.; Choi, J.Y.; Kim, S.B.; Uyangaa, E.; Hossain, F.M.; Park, S.Y.; Lee, J.H.; Eo, S.K. CCR5 ameliorates Japanese encephalitis via dictating the equilibrium of regulatory CD4(+)Foxp3(+) T and IL- 17(+)CD4(+) Th17 cells. J. Neuroinflamm. 2016, 13, 223, doi:10.1186/s12974-016-0656-x.
100. Netland, J.; Bevan, M.J. CD8 and CD4 T cells in West Nile virus immunity and pathogenesis. Viruses 2013, 5, 2573–2584, doi:10.3390/v5102573.
101. Betancourt, D.; de Queiroz, N.M.; Xia, T.; Ahn, J.; Barber, G.N. Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity. J. Immunol. 2017, 198, 3023–3028, doi:10.4049/jimmunol.1602180.
102. Chahal, J.S.; Fang, T.; Woodham, A.W.; Khan, O.F.; Ling, J.; Anderson, D.G.; Ploegh, H.L. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep. 2017, 7, 252, doi:10.1038/s41598-017-00193-w.
103. Pardi, N.; Hogan, M.J.; Pelc, R.S.; Muramatsu, H.; Andersen, H.; DeMaso, C.R.; Dowd, K.A.; Sutherland, L.L.; Scearce, R.M.; Parks, R., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017, 543, 248–251, doi:10.1038/nature21428.
104. Charrel, R.N.; Leparc-Goffart, I.; Pas, S.; de Lamballerie, X.; Koopmans, M.; Reusken, C. Background review for diagnostic test development for Zika virus infection. Bull. World Health Organ. 2016, 94, 574D–584D, doi:10.2471/BLT.16.171207.
105. Landry, M.L.; St George, K. Laboratory Diagnosis of Zika Virus Infection. Arch. Pathol. Lab. Med. 2017, 141, 60–67, doi:10.5858/arpa.2016-0406-SA.
106. US Food & Drug Administration Emergency Use Authorizations. Available online: https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika (accessed on 7 March 2017).
107. Rabe, I.B.; Staples, J.E.; Villanueva, J.; Hummel, K.B.; Johnson, J.A.; Rose, L.; Mts; Hills, S.; Wasley, A.; Fischer, M., et al. Interim Guidance for Interpretation of Zika Virus Antibody Test Results. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 543–546, doi:10.15585/mmwr.mm6521e1.
108. Huzly, D.; Hanselmann, I.; Schmidt-Chanasit, J.; Panning, M. High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses. Euro Surveill. 2016, 21, doi:10.2807/1560-7917.ES.2016.21.16.30203.
109. Felix, A.C.; Souza, N.C.; Figueiredo, W.M.; Costa, A.A.; Inenami, M.; da Silva, R.M.; Levi, J.E.; Pannuti, C.S.; Romano, C.M. Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection. J. Med. Virol. 2017, doi:10.1002/jmv.24789.
110. Steinhagen, K.; Probst, C.; Radzimski, C.; Schmidt-Chanasit, J.; Emmerich, P.; van Esbroeck, M.; Schinkel, J.; Grobusch, M.P.; Goorhuis, A.; Warnecke, J.M., et al. Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: A multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016, 21, doi:10.2807/1560-7917.ES.2016.21.50.30426.
111. Moulin, E.; Selby, K.; Cherpillod, P.; Kaiser, L.; Boillat-Blanco, N. Simultaneous outbreaks of dengue, chikungunya and Zika virus infections: Diagnosis challenge in a returning traveller with nonspecific febrile illness. New Microbes New Infect. 2016, 11, 6–7, doi:10.1016/j.nmni.2016.02.003.
112. Corman, V.M.; Rasche, A.; Baronti, C.; Aldabbagh, S.; Cadar, D.; Reusken, C.B.; Pas, S.D.; Goorhuis, A.; Schinkel, J.; Molenkamp, R., et al. Assay optimization for molecular detection of Zika virus. Bull. World Health Organ. 2016, 94, 880–892, doi:10.2471/BLT.16.175950.
113. Levine, M.M.; Sztein, M.B. Vaccine development strategies for improving immunization: The role of modern immunology. Nat. Immunol. 2004, 5, 460–464, doi:10.1038/ni0504-460.
114. WHO Vaccine Pipeline Tracker Zika. Available online: http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/ (accessed on 14 March 2017).
115. Lehrer, A.T.; Holbrook, M.R. Tick-borne Encephalitis Vaccines. J. Bioterror. Biodef. 2011, 2011, 3, doi:10.4172/2157-2526.S1-003.
116. McArthur, M.A.; Holbrook, M.R. Japanese Encephalitis Vaccines. J. Bioterror. Biodef. 2011, 2, doi:10.4172/2157-2526.S1-002.
117. Larocca, R.A.; Abbink, P.; Peron, J.P.; Zanotto, P.M.; Iampietro, M.J.; Badamchi-Zadeh, A.; Boyd, M.; Ng’ang’a, D.; Kirilova, M.; Nityanandam, R., et al. Vaccine protection against Zika virus from Brazil. Nature 2016, 536, 474–478, doi:10.1038/nature18952.
118. Yang, Y.; Shan, C.; Zou, J.; Muruato, A.E.; Bruno, D.N.; de Almeida Medeiros Daniele B.; Vasconcelos, P.F.; Rossi, S.L.; Weaver, S.C.; Xie, X., et al. A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika Vaccine. EBioMedicine 2017, 17, 145–156, doi:10.1016/j.ebiom.2017.02.003.
119. Abbasi, J. First Inactivated Zika Vaccine Trial. JAMA 2016, 316, 2588, doi:10.1001/jama.2016.19328.
120. Danko, J.R.; Beckett, C.G.; Porter, K.R. Development of dengue DNA vaccines. Vaccine 2011, 29, 7261–7266, doi:10.1016/j.vaccine.2011.07.019.
121. Ledgerwood, J.E.; Pierson, T.C.; Hubka, S.A.; Desai, N.; Rucker, S.; Gordon, I.J.; Enama, M.E.; Nelson, S.; Nason, M.; Gu, W., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 2011, 203, 1396–1404, doi:10.1093/infdis/jir054.
122. Martin, J.E.; Pierson, T.C.; Hubka, S.; Rucker, S.; Gordon, I.J.; Enama, M.E.; Andrews, C.A.; Xu, Q.; Davis, B.S.; Nason, M., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 2007, 196, 1732–1740, doi:10.1086/523650.
123. Beckett, C.G.; Tjaden, J.; Burgess, T.; Danko, J.R.; Tamminga, C.; Simmons, M.; Wu, S.J.; Sun, P.; Kochel, T.; Raviprakash, K., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29, 960–968, doi:10.1016/j.vaccine.2010.11.050.
124. Abbasi, J. Zika Vaccine Enters Clinical Trials. JAMA 2016, 316, 1249, doi:10.1001/jama.2016.12760.
125. Dowd, K.A.; Ko, S.Y.; Morabito, K.M.; Yang, E.S.; Pelc, R.S.; DeMaso, C.R.; Castilho, L.R.; Abbink, P.; Boyd, M.; Nityanandam, R., et al. Rapid development of a DNA vaccine for Zika virus. Science 2016, 354, 237–240, doi:10.1126/science.aai9137.
126. Kramps, T.; Elbers, K. Introduction to RNA Vaccines. Methods Mol. Biol. 2017, 1499, 1–11, doi:10.1007/978-1-4939-6481-9_1.
127. Richner, J.M.; Himansu, S.; Dowd, K.A.; Butler, S.L.; Salazar, V.; Fox, J.M.; Julander, J.G.; Tang, W.W.; Shresta, S.; Pierson, T.C., et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 2017, 169, 176, doi:10.1016/j.cell.2017.03.016.
128. Salam, A.P.; Rojek, A.; Dunning, J.; Horby, P.W. Clinical Trials of Therapeutics for the Prevention of Congenital Zika Virus Disease: Challenges and Potential Solutions. Ann. Intern. Med. 2017, doi:10.7326/M16-2530.
129. Adcock, R.S.; Chu, Y.K.; Golden, J.E.; Chung, D.H. Evaluation of anti-Zika virus activities of broadspectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay. Antivir. Res. 2017, 138, 47–56, doi:10.1016/j.antiviral.2016.11.018.
130. Balasubramanian, A.; Teramoto, T.; Kulkarni, A.A.; Bhattacharjee, A.K.; Padmanabhan, R. Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antivir. Res. 2017, 137, 141–150, doi:10.1016/j.antiviral.2016.11.015.
131. Barrows, N.J.; Campos, R.K.; Powell, S.T.; Prasanth, K.R.; Schott-Lerner, G.; Soto-Acosta, R.; Galarza- Munoz, G.; McGrath, E.L.; Urrabaz-Garza, R.; Gao, J., et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe 2016, 20, 259–270, doi:10.1016/j.chom.2016.07.004.
132. Bullard-Feibelman, K.M.; Govero, J.; Zhu, Z.; Salazar, V.; Veselinovic, M.; Diamond, M.S.; Geiss, B.J. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antivir. Res. 2017, 137, 134–140, doi:10.1016/j.antiviral.2016.11.023.
133. Xu, M.; Lee, E.M.; Wen, Z.; Cheng, Y.; Huang, W.K.; Qian, X.; Tcw, J.; Kouznetsova, J.; Ogden, S.C.; Hammack, C., et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med. 2016, 22, 1101–1107, doi:10.1038/nm.4184.
134. Zmurko, J.; Marques, R.E.; Schols, D.; Verbeken, E.; Kaptein, S.J.; Neyts, J. The Viral Polymerase Inhibitor 7-Deaza-2′-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Negl. Trop. Dis. 2016, 10, e0004695, doi:10.1371/journal.pntd.0004695.